Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    K Number
    K221271
    Date Cleared
    2022-07-27

    (86 days)

    Product Code
    Regulation Number
    880.6250
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    A patient examination gloves is a disposable device intended for medical purpose that is worn on the examiner's hand or fingers to prevent contamination between patient and examiner. In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTM D6978-05 Standard Practice for Assessment of Medical gloves to Permeation by Chemotherapy Drugs.

    Device Description

    The subject device is single use, disposable gloves intended for medical purposes to be worn on the examiner's hands to prevent contamination between patient and examiner. The gloves are powder-free, ambidextrous with beaded cuff, blue colored, nitrile, and tested for use with chemotherapy drugs. The gloves are offered in four sizes: extra-small, small, medium, large, and extra-large.

    AI/ML Overview

    The provided document describes the FDA 510(k) premarket notification for "Disposable Nitrile Powder-Free Examination Gloves (Tested for Use with Chemotherapy Drugs)". This document is for a medical device (gloves), not an AI/Software as a Medical Device (SaMD). Therefore, the concepts of acceptance criteria for AI performance, training/test sets, ground truth establishment by experts, MRMC studies, standalone algorithm performance, or a sample size for training data are not applicable to this submission.

    The "acceptance criteria" and "study that proves the device meets the acceptance criteria" in this context refer to the physical and chemical performance standards for the gloves, particularly their resistance to chemotherapy drugs and biocompatibility.

    Here's the information extracted from the provided text, tailored to the context of a physical medical device:


    Acceptance Criteria and Device Performance for Disposable Nitrile Powder-Free Examination Gloves

    The acceptance criteria for the Disposable Nitrile Powder-Free Examination Gloves are based on compliance with established international and national standards for medical gloves, particularly regarding their physical properties, freedom from holes, residual powder content, and resistance to permeation by chemotherapy drugs.

    1. Table of Acceptance Criteria and Reported Device Performance

    No.Test Methodology / StandardPurposeAcceptance CriteriaReported Device Performance
    1ISO 10993-10:2010 (Irritation & Skin Sensitization)Assess possible contact hazards from chemicals released from medical devices (skin/mucosal irritation, eye irritation, skin sensitization).Skin Sensitization Test: Grades less than 1, otherwise sensitization.Skin Irritation Test: Primary irritation index 0-0.4 (Negligible).Skin Sensitization Test: All grades are 0. All animals survived with no abnormal signs.Skin Irritation Test: Primary irritation index is 0. Response categorized as negligible.
    2ISO 10993-5:2009 (In Vitro Cytotoxicity)Assess in vitro cytotoxicity of medical devices.Viability reduced to <70% of the blank indicates cytotoxic potential.Viability of 100% test article extract is 17.1%. This means the device has potential toxicity to L-929 in the MTT method. (See further analysis in section below).
    3ISO 10993-11: 2017 (Systemic Toxicity)Evaluate potential for medical device materials to cause adverse systemic reactions.Within 72 h, if the toxicosis response of testing group is not greater than control group, sample is acceptable.No evidence of systemic toxicity from the extract.
    4ASTM D6124-06 (Reapproved 2017) (Residual Powder)Determine amount of residual powder on medical gloves.Powder residue limit of 2.0 mg.0.15-0.19 mg /glove.
    5ASTM D5151-19 (Holes in Medical Gloves)Cover the detection of holes in medical gloves.Samples: 125 gloves, AQL: 2.5 (ISO 2859), Criterion ≤7 gloves for water leakage.No glove water leakage found.
    6ASTM D6319-19 (Nitrile Examination Gloves)Covers certain requirements for nitrile rubber gloves used in medical examinations. (Includes dimensions, physical properties, etc.)Dimensions: S: width 80±10mm, Length ≥220mm; M: width 95±10mm, Length ≥230mm; L: width 110±10mm, Length ≥230mm; XL: width 120±10mm, Length ≥230mm. Thickness: Finger ≥0.05mm, Palm ≥0.05mm.Physical Properties (Before Aging): Tensile Strength ≥14MPa, Ultimate Elongation ≥500%.Physical Properties (After Aging): Tensile Strength ≥14MPa, Ultimate Elongation ≥400%.Dimensions (Examples from 3 lots): S: width 84-87mm, Length 244-257mm; M: width 88-96mm, Length 237-266mm; L: width 90-110mm, Length 240-263mm; XL: width 110-119mm, Length 245-262mm.Thickness: Finger 0.09-0.21mm, Palm 0.06-0.15mm. (All reported values meet or exceed the minima/ranges).Physical Properties (Before Aging): Tensile Strength 14.1-29.8 MPa, Ultimate Elongation 500.492% - 670.613%.Physical Properties (After Accelerated Aging): Tensile Strength 14.1-23.9 MPa, Ultimate Elongation 411.403% - 599.996%. (All reported values meet or exceed the minima).
    7ASTM D6978-05 (Reapproved 2019) (Chemotherapy Drug Permeation)Assessment of resistance of medical gloves to permeation by chemotherapy drugs, determining minimum breakthrough times.Specified Breakthrough Detection Times for Various Drugs: - Carmustine (BCNU) 3.3 mg/ml: 22.8 Minutes (min.)- Cisplatin 1.0 mg/ml: > 240 Minutes- Cyclophosphamide (Cytoxan) 20.0 mg/ml: > 240 Minutes- Dacarbazine 10 mg/ml: > 240 Minutes- Doxorubicin 2.0 mg/ml: > 240 Minutes- Etoposide 20.0 mg/ml: > 240 Minutes- Fluorouracil 50.0 mg/ml: >240 Minutes- Paclitaxel 6.0 mg/ml: >240 Minutes- Thio Tepa 10.0 mg/ml: 46.8Minutes (min.)Reported Breakthrough Detection Times: (Matches acceptance criteria values exactly, indicating compliance).- Carmustine (BCNU) 3.3 mg/ml: 22.8(23.7, 22.8, 23.1) Minutes- Cisplatin 1.0 mg/ml: > 240 Minutes- Cyclophosphamide (Cytoxan) 20.0 mg/ml: > 240 Minutes- Dacarbazine 10 mg/ml: > 240 Minutes- Doxorubicin 2.0 mg/ml: > 240 Minutes- Etoposide 20.0 mg/ml: > 240 Minutes- Fluorouracil 50.0 mg/ml: >240 Minutes- Paclitaxel 6.0 mg/ml: >240 Minutes- Thio Tepa 10.0 mg/ml: 46.8(48.2, 48.6, 46.8) Minutes.Warning: Low permeation times for Carmustine (BCNU) and Thio Tepa are noted, with a warning not to use with these specific drugs given their breakthrough times.

    2. Sample Size Used for the Test Set and Data Provenance

    The document describes material and performance testing, not a "test set" in the sense of an AI model's dataset. The "samples" refer to physical gloves selected for testing.

    The provenance of the data is from laboratory testing conducted on the manufactured gloves. The specific country of origin for the testing itself is not explicitly stated, but the manufacturer is Shandong Maida Medical Technology Co.,Ltd. in China. The testing is prospective in the sense that newly manufactured gloves are tested to ensure they meet the standards.

    • ASTM D5151 (Detection of Holes): Sample size for water leakage test: 125 gloves.
    • ASTM D6319 (Dimensions & Physical Properties): Results are shown for multiple lots (e.g., Lot no.: 210515, 210518, 210520), indicating multiple samples were tested across different manufacturing batches. The exact number of gloves per lot for each physical test (e.g., tensile strength, elongation) is not specified but would be defined by the ASTM standard.
    • ASTM D6978 (Chemotherapy Permeation): The results provide triplet values for Carmustine and Thio Tepa (e.g., 22.8(23.7, 22.8, 23.1)), suggesting three independent measurements were taken for these drugs. The standard itself specifies the number of replicates.
    • Biocompatibility Testing: The number of animal subjects used for the animal irritation, sensitization, and systemic toxicity tests is not specified in the summary but would conform to the respective ISO standards.

    3. Number of Experts Used to Establish Ground Truth and Qualifications

    This section is not applicable as the evaluation involves standardized laboratory testing against defined physical and chemical properties, not human expert interpretation of subjective data or images. The "ground truth" is defined by the objective measurement results according to the specified ASTM and ISO standards.

    4. Adjudication Method for the Test Set

    This is not applicable. Adjudication methods (like 2+1, 3+1) are for resolving discrepancies in human expert assessments (e.g., in medical image interpretation). Here, numerical test results from standardized methods are directly compared against established quantitative or qualitative acceptance criteria.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

    This is not applicable. MRMC studies are used to evaluate diagnostic imaging systems or AI tools where human readers are involved. This submission is for a physical medical glove.

    6. Standalone (Algorithm Only) Performance

    This is not applicable. This concept applies to AI/software performance. The device is a physical glove, not an algorithm.

    7. Type of Ground Truth Used

    The ground truth used is based on objective, quantitative measurements derived from standardized laboratory tests (bench testing) and biological responses observed in validated biocompatibility assays according to international standards (ASTM and ISO). This includes:

    • Quantitative Thresholds: e.g., minimum tensile strength, maximum residual powder, minimum breakthrough time for chemotherapy drugs.
    • Qualitative Observations (Biological): e.g., absence of irritation or sensitization, absence of systemic toxicity.
    • Conformity to Standards: The device's performance is compared directly to the specified requirements within each standard (e.g., ASTM D6319-19 dimensions, physical properties).

    One point of note is the cytotoxicity result (17.1% viability) which is below the 70% threshold, indicating cytotoxicity. The document addresses this by stating: "Analysis3: The proposed device is potentially cytotoxic, but all proposed devices are conducted the systemic toxicity test." And the systemic toxicity test showed "no evidence of systemic toxicity." This implies that despite the in vitro cytotoxicity, the manufacturer argues that in vivo systemic toxicity (which is generally considered a more critical endpoint for patient safety) was not observed, suggesting the findings are acceptable for the device's intended use according to the biocompatibility evaluation framework.

    8. Sample Size for the Training Set

    This is not applicable. There is no "training set" in the context of a physical device. The manufacturing process is controlled to produce gloves consistently, and batch testing ensures quality.

    9. How the Ground Truth for the Training Set Was Established

    This is not applicable. As there is no training set, the establishment of ground truth for it is irrelevant. The manufacturing process is designed and verified to produce products meeting the specified design and performance criteria.

    Ask a Question

    Ask a specific question about this device

    K Number
    K220488
    Date Cleared
    2022-06-01

    (99 days)

    Product Code
    Regulation Number
    880.6250
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    A patient examination gloves is a disposable device intended for medical purpose that is worn on the examiner's hand or fingers to prevent contamination between patient and examiner. In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTM D6978-05 Standard Practice for Assessment of Medical gloves to Permeation by Chemotherapy Drugs.

    Device Description

    The subject device is single use, disposable gloves intended for medical purposes to be worn on the examiner's hands to prevent contamination between patient and examiner. The gloves are powder-free, ambidextrous with beaded cuff, blue colored, nitrile, and tested for use with chemotherapy drugs. The gloves are offered in four sizes: small, medium, large, and extra-large.

    AI/ML Overview

    This document describes the acceptance criteria and the study proving that the "Disposable Nitrile Powder-Free Examination Gloves (Tested for Use with Chemotherapy Drugs)" meet these criteria.

    1. Table of Acceptance Criteria and Reported Device Performance:

    The device was tested against several standards, as detailed in the "Summary of Non-Clinical Testing" section (pages 8-13). Here's a summary:

    No.Test/StandardAcceptance CriteriaReported Device Performance
    1ISO 10993-10:2010 (Skin Sensitization)Grades less than 1.All grades were 0. All animals survived with no abnormal signs. The device is not a sensitizer.
    2ISO 10993-10:2010 (Skin Irritation)Primary irritation index of 0-0.4 for "Negligible" response.The primary irritation index was 0. The response was categorized as negligible. The device is not an irritant.
    3ISO 10993-5:2009 (In Vitro Cytotoxicity)Viability ≥ 70% of the blank (if viability is reduced to <70%, it has cytotoxic potential).Viability of 100% test article extract was 21.0%. This indicates potential toxicity to L-929 in the MTT method. (However, refer to Analysis3 in the document stating that systemic toxicity test showed the device is safe despite potential cytotoxicity).
    4ISO 10993-11:2017 (Systemic Toxicity)Within 72h, test group toxicosis response not greater than control group.No evidence of systemic toxicity from the extract.
    5ASTM D6124-06 (Residual Powder)Powder residue limit of 2.0 mg per glove.0.09-0.11 mg per glove.
    6ASTM D5151-06 (Freedom from Holes)Samples number: 125 gloves. AQL: 2.5 (ISO 2859). Criterion ≤7 gloves for water leakage.No glove water leakage found.
    7ASTM D6319-10 (Physical Properties - Sterility, Dimensions, Tensile Strength, Ultimate Elongation)Sterility: No need (Non-sterile device) Freedom from holes: Refer to No. 6 Dimensions: Length S: ≥220mm; M, L, XL: ≥230mm. Width S: 80±10mm; M: 95±10mm; L: 110±10mm; XL: 120±10mm. Thickness: Finger ≥0.05mm; Palm ≥0.05mm. Before Aging: Tensile strength ≥ 14MPa; Ultimate Elongation ≥ 500%. After Accelerated Aging: Tensile strength ≥ 14MPa; Ultimate Elongation ≥ 400%.Sterility: N.A. Freedom from holes: Refer to No. 6. Dimensions: Lot 210515: S: LxW 245-254mm x 82-85mm; M: LxW 249-255mm x 91-94mm; L: LxW 252-260mm x 102-105mm; XL: LxW 250-262mm x 112-115mm. Thickness F: 0.11-0.12mm; P: 0.08mm. Lot 210518: S: LxW 252-255mm x 83-85mm; M: LxW 250-256mm x 91-96mm; L: LxW 254-261mm x 101-106mm; XL: LxW 254-258mm x 111-116mm. Thickness F: 0.11mm; P: 0.08mm. Lot 210520: S: LxW 246-250mm x 82-86mm; M: LxW 245-249mm x 91-95mm; L: LxW 252-259mm x 103-107mm; XL: LxW 254-258mm x 112-116mm. Thickness F: 0.11-0.12mm; P: 0.07-0.08mm. Before Aging: Tensile strength 15.2-24.4 MPa; Ultimate Elongation 525.655% - 798.544%. After Accelerated Aging: Tensile strength 14.0-18.7MPa; Ultimate Elongation 578.552% - 745.388%.
    8ASTM D6978-05 (Chemotherapy Drug Permeation)Minimum breakthrough detection times for various chemotherapy drugs (specified in the Indications for Use and Table 4 of the 510(k) summary).Carmustine (BCNU) 3.3 mg/ml: 23.6 Minutes (min.) Cisplatin 1.0 mg/ml: > 240 Minutes Cyclophosphamide (Cytoxan) 20.0 mg/ml: > 240 Minutes Dacarbazine 10 mg/ml: > 240 Minutes Doxorubicin HCl 2.0 mg/ml: > 240 Minutes Etoposide 20.0 mg/ml: > 240 Minutes Fluorouracil 50.0 mg/ml: >240 Minutes Methotrexate, 25 mg/ml: >240 Minutes Mitomycin C, 0.5 mg/ml: >240 Minutes Paclitaxel 6.0 mg/ml: >240 Minutes Thio Tepa 10.0 mg/ml: 37.4 Minutes (min.) Vincristine Sulfate, 1mg/ml: >240 Minutes

    2. Sample Size Used for the Test Set and Data Provenance:

    The document provides the following details:

    • ASTM D5151 (Freedom from Holes): Sample size of 125 gloves. The provenance of this data (e.g., country of origin, retrospective/prospective) is not explicitly stated but is implied to be from laboratory testing conducted as part of the regulatory submission process.
    • For other tests (Biocompatibility, Physical Properties, Chemotherapy Drug Permeation), specific sample sizes are not detailed in the provided text. However, testing was stated to be "in accordance with the following standards" (ISO and ASTM), which would implicitly define minimum sample sizes for each test method. Data provenance is implied to be from laboratory testing.

    3. Number of Experts Used to Establish Ground Truth and Qualifications:

    This information is not provided in the document. The tests conducted are laboratory-based and follow established international and national standards (ISO, ASTM). The "ground truth" for these tests is defined by the methodologies and performance requirements within these standards, not by expert consensus in a clinical sense.

    4. Adjudication Method for the Test Set:

    This information is not applicable as the tests are laboratory performance tests following well-defined standards, not clinical studies requiring independent adjudication of outcomes.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

    This information is not applicable as the device is a medical glove, and the studies are pre-market non-clinical performance and biocompatibility evaluations. It is not an AI-assisted diagnostic device or a device where human reader performance would be a relevant metric.

    6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study:

    This information is not applicable as the device is a medical glove, not an algorithm or AI system. The performance evaluated is the physical and chemical resistance of the glove itself.

    7. Type of Ground Truth Used:

    The ground truth for the evaluations is based on:

    • Standardized Laboratory Test Results: Defined by the methodologies and acceptance criteria specified in the referenced ASTM and ISO international standards (e.g., specific tensile strength values, breakthrough times, chemical concentrations).
    • Biocompatibility Endpoints: As defined by ISO 10993 standards (e.g., absence of irritation, sensitization, systemic toxicity).

    8. Sample Size for the Training Set:

    This information is not applicable. This is a physical medical device, not a machine learning model that requires a training set.

    9. How the Ground Truth for the Training Set Was Established:

    This information is not applicable for the same reason as point 8.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1